Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 8/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | LCAT | P04180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17925061 | 0.78 | PANK3 (0.42) | PANK3CHRM4DPP4CHRM2CNR2 | |
| SCHEMBL21853959 | 0.78 | PANK3 (0.48) | PANK3CHRM4DPP4 | |
| SCHEMBL21853925 | 0.77 | PANK3 (0.49) | PANK3DPP4 | |
| SCHEMBL19748850 | 0.76 | PANK3 (0.61) | PANK3CHRM4DPP4CNR2 | |
| SCHEMBL16432851 | 0.76 | KCNJ1 (0.48) | PANK3 | |
| SCHEMBL21853983 | 0.75 | TIPARP (0.46) | PANK3 | |
| SCHEMBL16430700 | 0.74 | RET (0.57) | PANK3GPR119 | |
| SCHEMBL21853933 | 0.74 | KCNJ1 (0.46) | PANK3 | |
| SCHEMBL3084062 | 0.74 | CYP2C9 (0.52) | — | |
| SCHEMBL3554487 | 0.73 | CHRM4 (0.51) | PANK3CHRM4DPP4CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027625-B1 | SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9751881-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2016-07-21 | — | — | US | disclosed |
| EP-3027625-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017305-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP (US) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207922-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | PANK3 490/4885CHRM4 2709/4885DPP4 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.